242 related articles for article (PubMed ID: 32783421)
1. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
[TBL] [Abstract][Full Text] [Related]
2. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
3. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
[TBL] [Abstract][Full Text] [Related]
4. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
5. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
6. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
7. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
8. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
10. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
[TBL] [Abstract][Full Text] [Related]
11. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
12. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
15. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery: The PROMISE Trial.
Song W; Conti TF; Gans R; Conti FF; Silva FQ; Saroj N; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):170-178. PubMed ID: 32211907
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
Parca O; Cetin EN
Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
[TBL] [Abstract][Full Text] [Related]
20. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]